Abstract
Background:
Hepatocellular carcinoma exhibits high heterogeneity regarding its molecular and cellular characteristics. Biochanin A (Bio-A) has demonstrated promising clinical anti-tumor effects.
Purpose:
This study aimed to examine the effects of Bio-A treatment on the proliferation, apoptosis, invasion, and migration of the human hepatocellular carcinoma cell line HepG2.
Methods:
HepG2 cells were treated with varying concentrations of Biochanin A. The MTT assay was employed to assess cell proliferation, the scratch test was utilized to evaluate cell migration, and flow cytometry was conducted to analyze the cell cycle. Potential targets were identified through network pharmacology and subsequently verified via molecular docking.
Results:
Bio-A treatment significantly inhibited the proliferation and migration of HepG2 cells (p < 0.05). There was a significant increase in the proportion of cells in the G1/G0 phase in the Bio-A group (p < 0.05). A total of 16 intersection targets between Bio-A and liver cancer were identified through bioinformatics analysis. The potential targets were predominantly enriched in cancer-related signaling pathways. Molecular docking confirmed that Bio-A formed stable complexes with NCOA3 and PPARG.
Conclusion:
Biochanin A exerts a significant inhibitory effect on the biological functions of HepG2 cells.
Keywords
Get full access to this article
View all access options for this article.